Fred E. Cohen - 05 Jan 2026 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: Director
Signature: /s/ James Basta, attorney-in-fact
Issuer symbol: NTLA
Transactions as of: 05 Jan 2026
Net transactions value: +$1,402,500
Form type: 4
Filing time: 07 Jan 2026, 16:05:06 UTC
Previous filing: 17 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cohen Fred E	Director	C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET; SUITE 130, CAMBRIDGE	/s/ James Basta, attorney-in-fact	07 Jan 2026	0001339358

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Purchase	$1,402,500	+150,000	+261%	$9.35	207,453	05 Jan 2026	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person in accordance with the Issuer's trading policies.
F2	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.13 to $9.68, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on January 5, 2026 at each separate price.

Content

Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person in accordance with the Issuer's trading policies.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.13 to $9.68, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on January 5, 2026 at each separate price.